IP Library Granted Patent US 11,987,580
Granted Patent B2
US 11,987,580 · App. 17/559,488 · Granted May 21, 2024

Bicyclic inhibitors of histone deacetylase

Inventors: Nathan Oliver Fuller (Arlington, MA); John A. Lowe, III (Stonington, CT)
Assignee: Alkermes, Inc.
C07D471/04A61K31/437A61K31/519A61P25/28C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,987,580
App. No.
17/559,488
Granted
May 21, 2024
Kind
B2
Abstract

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2). The compounds are bicyclic inhibitors of histone deacetylase, useful for treating neurological disorders, memory or cognitive function disorders or impairments, extinction learning disorders, fungal diseases or infections, inflammatory diseases, hematological diseases, neoplastic diseases, psychiatric disorders, and memory loss.

Claims (33)

1. A method of treating Alzheimer's disease, Huntington's disease, fronto-temporal lobar degeneration, Friedreich's ataxia, post-traumatic stress disorder, Parkinson's disease, Parkinson's disease dementia, substance dependence recovery, memory or cognitive function disorder or impairment, neurological disorder with synaptic pathology, disorder of learning distinction, psychiatric disorders, cognitive function or impairment associated with Alzheimer's disease, Lewy body dementia, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, Fragile X, multiple sclerosis, age associated memory impairment, age related cognitive decline, and social, cognitive and learning disorders associated with autism in a subject in need thereof, comprising administering to the subject an effective amount of a compound having the Formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the condition is selected from Alzheimer's disease, Parkinson's disease, Parkinson's disease dementia, Huntington's disease, and Lewy body dementia.

3. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (5)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073790/0950 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (072656/0509) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES, INC.
Reel/Frame 074858/0481 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 072656/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2024
From: FULLER, NATHAN OLIVER; LOWE, JOHN A., III
To: RODIN THERAPEUTICS, INC.
Reel/Frame 066471/0802 →
CHANGE OF NAME Recorded Feb 15, 2024
From: RODIN THERAPEUTICS, INC.
To: ALKERMES, INC.
Reel/Frame 066472/0006 →